Journal
MEDIATORS OF INFLAMMATION
Volume 2016, Issue -, Pages -Publisher
HINDAWI LTD
DOI: 10.1155/2016/2847232
Keywords
-
Categories
Funding
- Ministry of Education and Science of the Russian Federation [RFMEFI60714X0061]
- Pharmsynthez OJSC (Saint Petersburg, Russia)
Ask authors/readers for more resources
have previously shown that immunodominant MBP peptides encapsulated in mannosylated liposomes (Xemys) effectively suppressed experimental allergic encephalomyelitis (EAE). Within the frames of the successfully completed phase I clinical trial, we investigated changes in the serum cytokine profile after Xemys administration in MS patients. We observed a statistically significant decrease of MCP-1/CCL2, MIP-1 beta/CCL4, IL-7, and IL-2 at the time of study completion. In contrast, the serum levels of TNF-alpha were remarkably elevated. Our data suggest that the administration of Xemys leads to a normalization of cytokine status in MS patients to values commonly reported for healthy subjects. These data are an important contribution for the upcoming Xemys clinical trials.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available